The successful employment of Brentuximab Vedotin to a patient with peritoneal dialysis: A case report

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports Pub Date : 2025-03-15 DOI:10.1016/j.cpccr.2025.100363

Sunpil Hwang , Sucheta Kundu , Brett Barlow

{"title":"The successful employment of Brentuximab Vedotin to a patient with peritoneal dialysis: A case report","authors":"Sunpil Hwang , Sucheta Kundu , Brett Barlow","doi":"10.1016/j.cpccr.2025.100363","DOIUrl":null,"url":null,"abstract":"<div><div>Brentuximab Vedotin, an antibody-drug conjugate targeting CD30, has been widely used in treating systemic anaplastic large-cell lymphoma and primary cutaneous anaplastic large-cell lymphoma. Despite its extensive use, information on its use in patients with end-stage renal disease is limited. This case report illustrates a 75-year-old male undergoing daily peritoneal dialysis, diagnosed with primary cutaneous anaplastic large-cell lymphoma. Due to extensive lesions, the patient opted for Brentuximab Vedotin following an exhaustive discussion. Remarkably, the treatment resulted in the complete resolution of cutaneous lesions, which was confirmed by a subsequent negative PET scan, indicating the absence of malignancy. Throughout the treatment course, the patient reported only weakness as a side effect, which was compounded by an acute COVID-19 infection at that time. This case report underscores the potential application of Brentuximab Vedotin in patients undergoing peritoneal dialysis, a population previously excluded, thus providing another promising therapeutic option for this particular population.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100363"},"PeriodicalIF":0.2000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621925000158","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Brentuximab Vedotin, an antibody-drug conjugate targeting CD30, has been widely used in treating systemic anaplastic large-cell lymphoma and primary cutaneous anaplastic large-cell lymphoma. Despite its extensive use, information on its use in patients with end-stage renal disease is limited. This case report illustrates a 75-year-old male undergoing daily peritoneal dialysis, diagnosed with primary cutaneous anaplastic large-cell lymphoma. Due to extensive lesions, the patient opted for Brentuximab Vedotin following an exhaustive discussion. Remarkably, the treatment resulted in the complete resolution of cutaneous lesions, which was confirmed by a subsequent negative PET scan, indicating the absence of malignancy. Throughout the treatment course, the patient reported only weakness as a side effect, which was compounded by an acute COVID-19 infection at that time. This case report underscores the potential application of Brentuximab Vedotin in patients undergoing peritoneal dialysis, a population previously excluded, thus providing another promising therapeutic option for this particular population.

查看原文本刊更多论文

布伦妥昔单抗韦多汀对腹膜透析患者的成功应用：一例报告

Brentuximab Vedotin是一种靶向CD30的抗体-药物偶联物，广泛用于治疗全身性间变性大细胞淋巴瘤和原发性皮肤间变性大细胞淋巴瘤。尽管其广泛使用，但其在终末期肾病患者中的应用信息有限。本病例报告显示一75岁男性每日接受腹膜透析，诊断为原发性皮肤间变性大细胞淋巴瘤。由于广泛的病变，在详尽的讨论后，患者选择Brentuximab Vedotin。值得注意的是，治疗导致皮肤病变完全消退，随后的PET阴性扫描证实了这一点，表明没有恶性肿瘤。在整个治疗过程中，患者只报告了虚弱的副作用，当时又出现了急性COVID-19感染。本病例报告强调Brentuximab Vedotin在腹膜透析患者中的潜在应用，这一人群以前被排除在外，因此为这一特定人群提供了另一种有希望的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊